Foamix Pharmaceuticals Ltd., an Israel-based clinical stage specialty pharmaceutical company with its U.S. headquarters in Bridgewater, announced it has appointed Matt Wiley its new chief commercial officer.
In this newly-created role, Wiley will be responsible for developing and executing commercial strategies for the company’s product portfolio of dermatological topical foams.
“Matt has an exceptional commercial record in pharmaceuticals and brings valuable experience and depth of knowledge in marketing, market access, and product launches,” David Domzalski, CEO of Foamix. “He will be a key addition to the Foamix team as we pursue regulatory filings for our lead candidates FMX101 for acne and FMX103 for rosacea and prepare to launch these products. We look forward to benefitting from his experience and insights as we transition to becoming a fully integrated, commercial stage company.”
Wiley, who has more than 20 years of commercial experience in the pharmaceutical industry, was previously at Jazz Pharmaceuticals for six years. Most recently, he was vice president of marketing and business unit lead for the company’s sleep disorder portfolio. Before Jazz, he was vice president of marketing at Azur Pharma. Earlier in his career, he held roles in sales, marketing and training at Guilford/MGI Pharma, Salix, Cephalon and Rhone-Poulenc Rover.
“Joining Foamix is a tremendous opportunity,” Wiley said. “I am enthusiastic about the commercial prospects for both FMX101 and FMX103 and their potential to address serious unmet needs in acne and rosacea. I look forward to leading the efforts to bring these products to market and contributing to Foamix’s success.”
